Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

计划入组 113 人 · 首次发布于 2013 年 6 月 12 日

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

计划入组 12 人 · 首次发布于 2019 年 9 月 20 日

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

计划入组 240 人 · 首次发布于 2021 年 3 月 12 日

WRN Inhibitors program (MSI-high tumors)

MSI-733

MSI-228

MSI ASIA PACIFIC

Australia

MSI Methylation Sciences Inc

Canada

BioLine Rx

Israel

Nimbus Therapeutics Initiates First-in-Human Trial of NDI-219216 for MSI-H Tumors Resistant to Standard Therapies

Nimbus Therapeutics Completes Dose Escalation for Novel WRN Inhibitor NDI-219216 in MSI-H Tumors

Nouscom Completes Enrollment in Phase 2 Trial of NOUS-209 for MSI Metastatic Colorectal Cancer